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Abstract
Background: The inhalation of normal or hypertonic saline during sputum induction (SI) may act
as an indirect bronchoconstrictive stimulus leading to dyspnea and lung function deterioration. Our
aim was to assess dyspnea and adverse events in COPD patients who undergo SI following a safety
protocol.
Methods: Sputum was induced by normal and hypertonic (4.5%) saline solution in 65 patients with
COPD of varying severity. In order to minimize saline-induced bronchoconstriction a protocol
based on the European Respiratory Society sputum induction Task group report was followed.
Dyspnea change was scored using the Borg scale and lung function was assessed by spirometry and
oximetry.
Results: Borg score changes [median(IQR) 1.5(0–2)] were observed during SI in 40 subjects; 16
patients required temporary discontinuation of the procedure due to dyspnea-general discomfort
and 2 did not complete the session due to dyspnea-wheezing. The change in Borg dyspnea score
was significantly correlated with oxygen saturation and heart rate changes and with discontinuation
of the procedure due to undesired symptoms. 19 subjects presented an hyperresponsive reaction
(decline>20% from baseline FEV1). No significant correlation between Borg changes and
FEV1decline was found. Patients with advanced COPD presented significantly greater Borg and
oxygen saturation changes than patients with less severe disease (p = 0.02 and p = 0.001,
respectively). Baseline FEV1, oxygen saturation and 6MWT demonstrated significant diagnostic
values in distinguishing subjects who develop an adverse physiologic reaction during the procedure.
Conclusion: COPD patients undergoing SI following a safety protocol do not experience major
adverse events. Dyspnea and oxygen desaturation is more likely to occur in patients with disease
in advanced stages, leading to short discontinuation or less frequently to termination of the
procedure. Baseline FEV1, oxygen saturation and 6MWT may have a prognostic value for the
development of these adverse events and might be useful to be evaluated in advance.
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Background
Induced sputum examination is a relatively non invasive
method standardized by Pin et al[1] as an alternative to
bronchoscopy procedure for collecting secretions and
inflammatory cells from the airways of subjects with
Chronic Obstructive Pulmonary Disease (COPD) and
bronchial asthma. The method consists of the induction
of airways secretions after the inhalation of progressively
increased concentrations of saline aerosol. It is more fea-
sible than bronchoscopy and is considered to provide
repeatable and valid results [2].
However, the inhalation of normal or hypertonic saline,
may also act as an indirect bronchoconstrictive stimulus
in subjects with airflow limitation, leading to further lung
function deterioration and worsening of symptoms such
as dyspnea[2]. Concerns about the safety of the procedure
have been raised especially after the report of a fatal
asthma attack, precipitated by inhalation of distilled
water[3]. In asthma, the method is considered safe when
standard guidelines are applied[4].
In COPD lung function deterioration has been reported
during the procedure [5-7]. European Respiratory Society
(ERS) sputum induction Task group report[5] has under-
lined the lack of systematic studies addressing safety issues
in patients with advanced COPD. In previous studies [6-
10] the main objective was mainly the lung function
changes and forced expiratory volume in one second
(FEV1) decline during SI but, little attention was paid in
the worsening of dyspnea. However, dyspnea develop-
ment during SI may affect the tolerability of the method
in COPD[8,10]. Thus, for research purposes or for clinical
studies investigating cells or mediators measurable in spu-
tum, it is important to realize the potential danger immi-
nent in this procedure and to improve the tolerability of
SI.
In the present study we performed SI by administrating
normal and hypertonic saline in a group of COPD
patients, as part of a longitudinal study of lung function
decline. Our primary aim was 1) to assess dyspnea and
adverse events during the procedure and, 2) to evaluate
the relation between dyspnea and lung function change or
oxygen desaturation that may occur during the procedure.
A secondary endpoint in this study was to determine the
diagnostic value of baseline parameters in distinguishing
patients who will experience an adverse reaction during
SI.
Methods
Subjects
Sixty five patients, 21 current smokers and 44 ex-smokers,
with stable COPD were recruited by consecutive sampling
from a cohort of a longitudinal study of lung function
decline in COPD and gave their consent to participate in
the study. The diagnosis of COPD was based on the Glo-
bal Initiative for Chronic Obstructive Lung Disease
(GOLD) consensus criteria[11]. All patients with COPD
had been free of an acute exacerbation for at least 4 weeks
before the study and had not received antibiotics or corti-
costeroids (oral or inhaled) over the same period. No sub-
ject had a history of asthma or allergic rhinitis. Twenty
patients had concomitant cardiovascular disease in stable
condition. The hospital ethical committee ('Agios Geor-
gios' Chania General Hospital, Crete, Greece) approved
the protocol.
Study design
Patients attended on two consecutive days. Short acting B2
agonists and/or anticholinergic inhalers were withheld for
a minimum of 8 hours and long acting B2 agonists for 12
hours before each visit. The subjects were followed for the
subsequent two weeks period in order to assign late
adverse events.
Baseline assessment (visit 1)
Baseline characteristics were evaluated[12] and 6MWT
was performed according to standardized guidelines[13].
The 6MWT was performed indoors about the same time of
day, along a 100-feet flat, straight, enclosed hallway with
a hard surface that was seldom travelled. The walking
course was 30 meters in length and it was marked every 3
meters. Instructions to patients were given according to
accepted recommendations[13]. The patient should sit at
rest in a chair, located near the starting position, for at
least 10 minutes before the test started. Clothing and
shoes should be appropriate for walking. During that
time, oxygen saturation, pulse and blood pressure were
measured and baseline dyspnea was assessed using the
Borg scale. A physician should stand near the starting line
during the test without walking with the patient. Only the
standardized phrases for encouragement[13] were used
during the test. When test was finished postwalk Borg dys-
pnea, oxygen saturation and pulse rate were recorded, as
well as the total distance covered.
Sputum induction (visit 2)
Sputum was induced via inhalation of saline solutions
aerosol, generated by an ultrasonic nebulizer (Ultraneb
2000; DeVilbSIs; Somerset, PA) modifying a previously
described protocol[14]. Aerosols of normal saline and
hypertonic saline (NaCl 4.5%) were inhaled for subse-
quent periods of 2 and 8 minutes each (4 periods, 20 min-
utes in total). The sample was determined to be adequate
if at least 1 ml of sputum was collected into a sterile con-
tainer.BMC Pulmonary Medicine 2006, 6:17 http://www.biomedcentral.com/1471-2466/6/17
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Adverse events
The patients were free to ask for discontinuation of the
procedure in case they experienced undesired symptoms.
At the end of sputum induction, they were asked to record
these symptoms in a chart. Any discontinuation of the
procedure due to undesired symptoms was termed as
"mild adverse event". Any discontinuation of the proce-
dure due to symptoms requiring acute medical pharma-
ceutical intervention-hospitalization was termed as
"major adverse event".
Dyspnea assessment
Perception of dyspnea during SI was defined as sensation
of bronchoconstriction or, chest tightness or, inability to
take a deep breath or, sensation of effort to breath. Dysp-
nea intensity was rated on the Borg dyspnea scale[15]
immediately before each lung function measurement and
at the end of sputum induction.
Lung function measurement and O2 desaturation
Spirometry was performed at baseline and at the end of
each time period with a computerized system (Lab, 2.12;
Jaeger; Wuerzburg, Germany). This system, which meets
the ATS standards, was calibrated every day with standard-
ized techniques according to guidelines[16]. Pulse oxi-
metric saturation (SpO2) was recorded immediately
before each FEV1  measurement using pulse oximetry
(Nonin 8500 M; Nonin Medical; Minneapolis, MN).
Safety protocol
In order to minimize the broncoconstrictive response to
saline inhalation, a safety protocol was followed. The pro-
tocol was based on the European Respiratory Society spu-
tum induction Task group report[5]:
a) All subjects were premedicated with 200 µg salbutamol
via metered-dose inhaler 30 minutes before spirometry.
b) If mild adverse events took place, clinical evaluation
was carried out. c) If major adverse events or life threaten-
ing adverse events occurred there was a termination of the
procedure and patients were treated appropriately. d)
Bronchodilators were administered at the end of SI in any
subject who experienced dyspnea or decline of FEV1>20%
from the baseline.
The reproducibility of the above was assessed on a pilot
study on 10 subjects. These subjects were chosen from the
outpatient clinics of Chania General Hospital, Crete,
Greece. Five of them were selected based on a physician's
diagnosis of stable COPD. The five other subjects chosen
from the list of non respiratory outpatient clinics did not
have any respiratory disease and did not complain of dys-
pnea. They were scheduled for two visits, 2 weeks apart.
They underwent SI and dyspnea was evaluated by the Borg
scale. The reproducibility in this sample was 95%.
Statistical analysis
Descriptive statistics were used to summarize the baseline
characteristics and the results were expressed as
means(SE) or stated otherwise. Normal distribution was
assessed using the Kolmogorov-Smirnov Z test. The inde-
pendent samples t-test was applied for the comparison of
approximately normally-distributed variables and the
Mann-Whitney U test where there was evidence of non-
normality. Categorical variables were compared using the
chi-square test. Borg score change (∆Borg), adverse events
were considered as outcome variables. Correlations
between outcome variables and clinical or lung function
variables were assessed appropriately either by Pearson's
r2 or by Spearman's rho. To determine the prognostic
value of various parameters in distinguishing patients
who will experience an adverse physiologic reaction
(∆Borg >0 and adverse events) during SI, receiver-operat-
ing-characteristic (ROC) curves were constructed to assign
cut-off values and their diagnostic utility. A p value of less
than 0.05 was considered as statistically significant. The
statistical package SPSS 13.0, (Chicago, IL, USA) was used
for the entire analysis.
Results
Patient's baseline characteristics are demonstrated in
Table 1. 60 subjects (92%) produced acceptable sputum
with a mean (SE) percentage viability 96(9) and squa-
mous cells contamination 17.5(12). All five subjects that
did not provide sufficient sputum samples experienced
adverse events during the procedure: 2 dyspnea (chest
tightness) – excessive wheezing; 2 dyspnea (sensation of
effort to breath) – general discomfort; 1 nausea. These
subjects presented significantly greater ∆Borg [3(1) versus
1.5(1) p = 0.001], ∆SpO2 [-2.5(-2) versus -1(1) p = 0.001]
Table 1: Baseline characteristics of all 65 COPD patients
Age, yrs 66(1)
M/F 60(92)/5(8)
Current/ex smokers 21(32)/44(68)
Pack years 53(3.9)
FEV1 (% predicted) 48(2.4)
FEV1/FVC 0.46(0.07)
Oxygen saturation % 92(0.4)
MRC dyspnea score 1 (0–4)
Chronic cough 44(6)
Chronic sputum 31(47)
Chronic wheeze 21(32)
Inhaled long acting b-agonists 41(63)
Inhaled corticosteroids 31(47)
6MWT, meters 311(18)
∆Borg6MWT 2.1(0.2)
Continuous data are expressed as mean (SE), categorical data are 
expressed as n (%), MRC score is expressed as median (range).BMC Pulmonary Medicine 2006, 6:17 http://www.biomedcentral.com/1471-2466/6/17
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and ∆FEV1 [-18(12) versus -10(8), p = 0.001], compared
to all other patients. Unsuccessful session of sputum
induction was more likely in the group of patients with
COPD of stage IV than in patients with less severe disease
[Relative Risk (RR) 18, 95%CI 1.7–80].
Adverse events
No major event requiring hospitalization occurred during
the procedure. 18 of the 65 patients presented 28 minor
adverse events: 16 dyspnea-general discomfort, 9 general
discomfort, 1 nausea; 2 did not complete the session due
to dyspnea-excessive wheezing. One patient with COPD
stage IV experienced a COPD exacerbation two days later
treated adequately at home. Patients with stage IV COPD
had a significantly increased risk to be in this subgroup
compared to patients with less severe disease (RR 2.9,
95%CI 1.4–6).
Borg score dyspnea
40 subjects (61%) demonstrated ∆Borg>0. These patients
had relatively advanced disease (Table 2), lower baseline
SpO2 [89(0.9) versus 93(0.4), p = 0.007], 6MWT (meters)
[227(18) versus 352(26), p = 0.007] (Figure 1), compared
to patients with ∆Borg = 0. Borg score changes were signif-
icantly greater in patients who experienced adverse events
compared to the rest of the patients (Figure 2). There were
no significant differences in ∆Borg between smokers and
ex-smokers [1.4(0.5) versus 1.2(0.4), respectively p =
0.11].
Lung function
The average decline of FEV1(∆FEV1) during the procedure
is demonstrated in Figure 3. The mean(SE) change in FEV1
was overall -9.9(2)% from the baseline. FEV1 had already
fallen by 9.5(2)% from the baseline 2 minutes after saline
inhalation. 19 subjects out of 61 (31%) presented an
hyperresponsive reaction to saline inhalation (loss of >
20% from the baseline FEV1).
Correlations between Borg score and oxygen desaturation, 
lung function
The average ∆Borg was significantly correlated with aver-
age ∆SpO2, (r = -0.38, p = 0.001) and adverse events (rho
= 0.51, p = 0.01). Significant correlations were also
present between the ∆Borg and ∆SpO2 when each time
period was studied separately: 0 to 2 minutes, 2 to 10 min-
utes, 10 to 12 minutes and 12 to 20 minutes (r = -0.26, p
= 0.01, r = -0.4, p = 0.002, r = -0.21, p = 0.01 and r = -0.45,
p = 0.001, respectively).
In contrast there were no significant correlations between
∆Borg and ∆FEV1 either considering the average or the val-
ues in each time period.
Table 2: Lung function, pulse oximetry and Borg dyspnea score during sputum induction, according to COPD severity.
Overall COPD severity (GOLD stages)
Stage I Stage II Stage III Stage IV
n = 65 n = 5 n = 24 n = 22 n = 14
Median (IQR) change* p-value
Borg 1.5 (0, -2) 0 (0, 1) 1 (0, 1) 1.5 (0, 2) 1.5 (0, 3) 0.02
SpO2 % -1 (0, -2) -0 (0, 0) -1 (0, -1.5) -1.5 (0, -3) -2.5 (-1.5, -3) 0.001
Heart rate 25 (10, 33) 15 (8, 22) 17 (10, 25) 21 (12, 29) 32(10, 45) 0.09
FEV1 -9.5 (-3, -15) -11 (-3, -17) -5 (0,-8) -12 (-3, -17) -9 (-3, -12) 0.32
* change from the post-bronchodilation baseline value
6MWT distance in COPD patients according to Borg dysp- nea score during sputum induction Figure 1
6MWT distance in COPD patients according to Borg 
dyspnea score during sputum induction. Group A rep-
resents patients with mean changes in Borg score = 0; Group 
B represents patients with mean changes in Borg score >0. 
Bars represent mean values.BMC Pulmonary Medicine 2006, 6:17 http://www.biomedcentral.com/1471-2466/6/17
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Diagnostics
Table 3 depicts the threshold values of various parameters
in distinguishing patients that presented an adverse phys-
iologic reaction during the procedure (defined as ∆Borg>0
+ adverse events). Among them, 6MWT and MRC score
demonstrated remarkable specificity with high positive
and negative predictive values, while post-bronchodila-
tion FEV1 demonstrated the highest sensitivity.
Discussion
This prospective study represents the largest systematic
report of adverse events and dyspnea evaluation during
sputum induction in COPD. Our results suggest that
COPD patients who undergo sputum induction, follow-
ing a safety protocol, do not experience major adverse
events. However, the patients may have an increase per-
ception of dyspnea [overall increase in Borg score
median[(IQR) 1.5(0–2)] and desaturation and may
require short discontinuation of the procedure due to
undesired symptoms. We found that dyspnea changes
during sputum induction were significantly correlated
with oxygen saturation, heart rate changes and mild
adverse events. This adverse physiologic reaction was
more frequent in subjects with advanced COPD. Notably,
patients of stage IV in GOLD staging of severity, presented
an increase risk to have unsuccessful sputum induction
and to have minor adverse events during the procedure
compared to patients with less severe disease (RR 2.9,
95%CI 1.4–6). In addition we found that the baseline val-
ues of post-bronchodilation FEV1, of oxygen saturation
Borg score changes in COPD patients during sputum induction, according to adverse events and success of procedure Figure 2
Borg score changes in COPD patients during sputum induction, according to adverse events and success of 
procedure. Individual values of average changes in Borg dyspnea scale during sputum induction. Mild adverse events were 
defined as discontinuations of the procedure due to undesired symptoms including dyspnea (sensation of bronchoconstriction, 
chest tightness, inability to take a deep breath, sensation of effort to breath), wheezing, nausea. Open circles represent patients 
that completed the procedure successfully; closed circles represent patients that did not complete the procedure successfully 
due to mild adverse events.BMC Pulmonary Medicine 2006, 6:17 http://www.biomedcentral.com/1471-2466/6/17
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and of 6MWT have a diagnostic value in distinguishing
patients who develop an adverse reaction during SI. To the
best of our knowledge this has not been reported.
In previous studies addressing SI safety in COPD, the
measurement of FEV1 was considered enough to diagnose
acute lung responses[6,7,9]. However, an excessive fall in
FEV1 during SI is not always associated with clinical dete-
rioration[9] or dyspnea development[6]. Thus, it is not
unlikely that assessing only FEV1 during the procedure,
early signs of clinical deterioration may be undetected.
Consequently, the development of adverse events may
affect the tolerability of the procedure[8,9]. In our study,
special attention was paid to evaluate dyspnea, in addi-
tion to FEV1 assessment. We found that patients undergo-
ing SI may experience an adverse physiologic reaction,
characterized by worsening of dyspnea, undesired symp-
toms and oxygen desaturation. This adverse reaction was
not significantly related to FEV1 decline but affected the
tolerability of the procedure in a proportion of patients.
This may have importance in research or clinical studies,
especially in patients with advanced disease.
In the studied population, we included subjects with
advanced disease since European Respiratory Society
report has underlined the lack of systematic studies in this
category of patients[5]. Normal and hypertonic saline was
administered even in subjects with very severe disease. We
found that COPD patients experienced significant Borg
score and oxygen saturation changes, associated with dis-
ease severity. COPD subjects of stage IV had an increased
risk of developing dyspnea, requiring subsequently dis-
continuation of the procedure. The degree of discomfort
led eight out of 14 (57%) patients in this category to tem-
porary discontinuation and two of them (14%) to early
termination of the procedure. In addition, 4 out of 5
patients who did not provide sufficient sputum sample,
had stage IV COPD. Hence, patients with advanced COPD
may experience excessive dyspnea during sputum induc-
tion and they might be reluctant to repeat the procedure
in the future. Therefore, sputum induction in this category
of patients must be performed with great caution and in
the ground of our findings careful monitoring of oxygen
saturation and dyspnea is essential.
In the present study all subjects were premedicated with
salbutamol. B2-agonists and anticholinergic inhalers were
withheld before SI in order to standardize further our
assessment. It is known that inhaled salbutamol does not
provide full protection from bronchoconstriction as it has
been demonstrated by the adverse responses after saline
inhalation[7,9]. However, it remains unclear whether the
magnitude of bronchoconstriction could be prevented by
pretreatment with larger doses of inhaled salbutamol or
with another type of bronchodilator or antinflammatory
treatment[9,10]. A prospective study is necessary to test
this hypothesis.
In this study, 31% of the patients demonstrated an exces-
sive fall (>20%) of FEV1. According to previous reports,
excessive FEV1 decline ranges, between 11[6] and 50%[9],
depending on the COPD population studied. Interest-
ingly, we found that FEV1 decline had almost reached the
average decline 2 minutes after saline inhalation and that
FEV1 did not return to baseline during the procedure. In
previous studies in COPD patients[8-10], there hasn't
been any assessment before the 5th  minute following
saline inhalation. In these studies, the greatest decline in
FEV1 seems to occur constantly at the beginning of the
procedure, following similar time course patterns to our
assessments. The time course pattern of FEV1 could be
explained by the underlying mechanism of the bronchoc-
onstrictive response. The inhalation of normal or hyper-
tonic saline may trigger mast cell and basophil
degranulation, in response to an increase of airway osmo-
larity[17-20]. The release of bonchoconstrictive mediators
from mast cells is rapid and essentially completed by five
minutes[21]. In line with this early inflammatory
response, it has been reported in a time course assessment
study in asthmatic patients[18], that the maximal mean
fall in FEV1 occurs at 3 minutes post saline inhalation. In
this ground, premedication of the patients with bron-
chodilators should be a standard safety measure of the
FEV1 change during sputum induction Figure 3
FEV1 change during sputum induction. Percentage 
change in FEV1 with standard errors during sputum induction. 
Group A represents patients with mean changes in Borg 
score ≤0; Group B represents patients with mean changes in 
Borg score >0.BMC Pulmonary Medicine 2006, 6:17 http://www.biomedcentral.com/1471-2466/6/17
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procedure. Future studies of different design may identify
which is the most effective bronchodilator to prevent this
bronchoconstrictive response.
An interesting point in our study is that the development
of dyspnea and the fall of the FEV1 were not significantly
correlated. One would expect patients with the most
severe airway obstruction to be the most dyspnoeic. How-
ever, some patients with severe airway obstruction are
minimally symptomatic, whereas others with little objec-
tive dysfunction appear to be very dyspnoeic[22]. Several
studies have investigated the correlation between dyspnea
and lung function[23]. Mahler et al reported that dyspnea
and baseline pulmonary function are independent quan-
tities in patients with COPD[24]. Subsequent studies
employing newer techniques to quantify breathlessness
found either no significant or weak correlations with
FEV1[25,26]. Thus, an excessive fall in FEV1 is not always
correlated with symptoms development and with dyspnea
scale scores in COPD[6,9].
A reasonable explanation for this discrepancy between
FEV1 decline and clinical deterioration during SI, may be
the subjectiveness of dyspnea perception[27]. Unlike
asthmatic patients who experience episodic bronchocon-
striction, those with COPD demonstrate chronic airflow
limitation that might lead to desensitization. Ottanelli
and colleagues have previously reported that a reduced
perception of dyspnea during bronchoconstriction may
be present in COPD patients[28]. A reduced perception of
dyspnea might delay self referral or lead to underreport of
discomfort during the procedure. In addition, it may be
that some dyspnoeic patients in our study, did not
develop their "potential maximal" drop in FEV1, because
they felt discomfortably and interrupted the procedure
thus, demonstrating a submaximal effort in lung fuction
testing. Furthermore, dyspnea during a bronchoconstric-
tive challenge is associated not only to airway obstruction
but also to hyperinflation[29]. In fact, dyspnea perception
may be better related with acute hyperinflation than with
airflow obstruction sensation in patients with chronic air-
flow obstruction[28]. Patients with advanced COPD may
develop dynamic hyperinflation in the setting of a bron-
chocontrictive stimulus[9,29]. In the present study the
most severely affected patients in terms of baseline disease
severity presented the greatest perception of dyspnea dur-
ing SI. Thus, it is likely that a proportion of patients may
have experienced dyspnea during SI due to acute hyperin-
flation.
In this ground other lung function parameters may be
considered in addition to FEV1, when addressing safety in
SI. It has been demonstrated that forced inspiratory rather
than expiratory parameters were more sensitive in detect-
ing SI related lung function deterioration and were better
associated to dyspnea[9,30]. Forced inspiratory volume in
one second(FIV1) is less affected by airway collapse than
FEV1, reflecting obstruction and hyperinflation[9]. In
addition, acute inspiratory capacity changes (IC) account
in part for the variability in the perception of dyspnoea
after accounting for changes in FEV1 during bronchocon-
striction in patients with chronic airflow obstruction[28].
These data, along with the disassociation between dysp-
nea and FEV1 in our study, suggest that possibly other
parameters, like FIV1 or IC should be brought forward to
monitor lung function deterioration and adverse events
development, during SI. In this ground a new insight for
the reason of dyspnea during SI might also be provided.
However, the present study was designed to assess dysp-
nea intensity and adverse events during SI based on ERS
sputum induction task group report [5] and thus other
lung function parameters were not assessed.
In the present investigation, ∆Borg was significantly corre-
lated with ∆SpO2. However the correlations between dys-
pnoea intensity and oxygen saturation changes were
weak. A plausible explanation may be that the relation-
ship between hypoxia – ventilatory response and breath-
lessness in patients with COPD is not linear. Thus, the
level of breathlessness is related to hypoxaemia but not in
all levels of desaturation[31]. In addition, dyspnea sensa-
tion may result from pathophysiological abnormalities
Table 3: Diagnostic performance of baseline characteristics of COPD patients in distinguishing those with an adverse reaction during 
SI.
Cut-off value Sensitivity Specificity Positive predictive value Negative predictive value
A2ge >70 65 52 42 77
FEV1, (% pred) <40 83 64 47 91
∆SpO2 (%) ≤91 74 78 54 88
MRC score > 2 52 86 56 82
Borg >4 66 55 44 80
6MWT distance (m) ≤155 52 98 90 84
∆Borg6MWT >2 82 55 33 73
FEV1 = post-bronchodilation forced expiratory volume in one second; ∆SpO2 = oxygen saturation average changes; MRC = Medical Research 
Council; 6MWT = six minutes walking test; ∆Borg6MWT = Borg dyspnea score change after 6MWT.BMC Pulmonary Medicine 2006, 6:17 http://www.biomedcentral.com/1471-2466/6/17
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that can be related to non respiratory mechanisms[32].
Therefore, the weak correlations between dyspnea and
oxygen saturation changes could be attributable to other
factors (emotional, cognitive) which have not been evalu-
ated in the present study.
In the present study, we evaluated the diagnostic perform-
ance of baseline clinical characteristics of the patients
undergoing SI, in order to distinguish those who will
develop an adverse physiologic response during SI. This is
important because clinical parameters which can be meas-
ured in a simple way, before performing the test, give use-
ful information in advance. In addition, predictors of
adverse events and lung function deterioration during SI
are not yet widely known [6,9,27]. We found that the
development of dyspnoeic events during SI, could be bet-
ter predicted by the post-bronchodilation FEV1(%pred),
the MRC score, the oxygen saturation and the 6MWT. To
the best of our knowledge, this has not been reported
until now[5,7,10].
MRC score is a good predictor of exercise capacity. It has
showed a consistent relationship with Borg rating and a
significant correlation with breathlessness and dynamic
hyperinflation measured during walking[33]. Baseline
oxygen saturation is also reported to be associated with
the hypoxemia during inhalation provocative tests[34]. In
addition, our investigation showed that COPD patients
with good performance status, by means of walking more
than 155 meters during 6MWT, will be less prone to
develop dyspnea during the procedure. This is likely to be
due to dynamic hyperinflation. 6MWT performance is
associated to the oxygen uptake, to the severity of chronic
dyspnea in COPD patients and it may also be related with
the dynamic hyperinflation which is developed in
patients after certain stimuli[9,35]. We believe that since
subjects with moderate to severe COPD are characterized
by hyperinflation and low performance, 6MWT is possi-
bly a good predictor of developing dyspnea after a stimu-
lus such as the inhalation of saline [9,22].
In summary, we found that normal and hypertonic saline-
induced sputum is a safe technique, when certain precau-
tions are taken, in patients with COPD. It is safe even for
patients in an advanced stage of the disease. However,
excessive dyspnea is more likely to occur in these patients,
leading in temporary or permanent discontinuation,
affecting tolerance and success of the procedure. There-
fore, sputum induction must be performed with great cau-
tion and careful monitoring of dyspnea and oxygen
saturation in patients with very severe COPD. Post-bron-
chodilation FEV1(%pred), oxygen saturation and 6MWT
have a prognostic value for the development of dyspnea
during SI and it would be useful to be evaluated in
advance. We believe that this is important information
and favors further the improvement of SI safety and toler-
ance especially in advanced COPD.
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